United States Diabetic Nephropathy Market Insights Forecasts to 2033

• The Market Size is Growing at a CAGR of 5.7% from 2023 to 2033
• The U.S. Diabetic Nephropathy Market Size is Expected to Hold a Significant Share by 2033

The U.S. Diabetic Nephropathy Market Size is Anticipated to Hold a Significant Share by 2033, Growing at a CAGR of 5.7% from 2023 to 2033.

Market Overview

Diabetic nephropathy is another name for diabetic kidney disease that involves developing hypertension and hyperglycaemia, which cause a series of alterations in several pathways leading to morphological changes in the kidneys and finally causes kidney damage. Its importance in the field of healthcare makes it hold high prospects in the forecast period. Diabetes is one of the main conditions that shows microvascular damage to the kidney. The number of patients suffering from diabetes along with other comorbidities like hypertension and aging-related nephron loss is expected to result in kidney disease. This, in turn, is contributing to the growth in R&D activities for the treatment of the condition, hence aiding the market growth. With increased cooperation between pharmaceutical companies, research institutes, and health organizations, these said research efforts are further motivated to better understand the mechanisms responsible for diabetic nephropathy, as well as treatment strategies.

Report Coverage

This research report categorizes the market for the US diabetic nephropathy market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United States diabetic nephropathy market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the U.S. diabetic nephropathy market.

Driving Factors

The increase in awareness regarding the treatment of diabetes and more and more usage of combination therapy by the patients and healthcare professionals will drive further demand in the United States diabetic nephropathy market. The increase in R&D investments in drug discovery and development and rising prevalence of diabetes are expected to boost further the growth of the United States diabetic nephropathy market. The growing number of open angle glaucoma drugs available in retail pharmacies and the increasing number of retail pharmacies in country these are growth opportunities in the market. Patients also opt for retail pharmacies when buying drugs because these are easily accessible.

Restraining Factors

Lack of skilled personnel unaware of the knowledge of the treatment methods for this disease could curb the growth of the United States diabetic nephropathy market over a forecast period. The huge expenditure of the treatment methods surely hampers the market growth.

Market Segmentation

The US diabetic nephropathy market share is classified into drug class and distribution channel.

• The angiotensin receptor blockers segment is expected to hold a significant market share through the forecast period.

The United States diabetic nephropathy market is segmented by drug class into angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers, sodium glucose cotransporter 2 (SGLT2) inhibitors, mineralocorticoid receptor antagonists, and others. Among these, the angiotensin receptor blockers segment is expected to hold a significant market share through the forecast period. Many benefits are associated with the use of angiotensin receptor blocker that is driving the market growth. It prevents and delays the onset of nephropathy among diabetic patients with type 2 diabetes and microalbuminuria. It also enables diabetic patients to avoid developing any type of complication.

• The hospital pharmacies segment is expected to dominate the US market during the projected period.

Based on the distribution channel, the United States diabetic nephropathy market is divided into hospital pharmacies, drug stores & retail pharmacies, and others. Among these, the hospital pharmacies segment is expected to dominate the US diabetic nephropathy market during the projected period. This is attributed to chronic kidney disease has become common all over the country and people suffering from CKD have a high risk of health complications.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the United States diabetic nephropathy market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Janssen Pharmaceuticals, Inc
• AstraZeneca
• Aurobindo Pharma Limited
• Teva Pharmaceutical Industries Ltd
• Sanofi
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Bayer AG
• Par Pharmaceuticals
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at U.S., regional, and country levels from 2020 to 2033. Spherical Insights has segmented the United States diabetic nephropathy market based on the below-mentioned segments:

United States Diabetic Nephropathy Market, By Drug Class

• Angiotensin Converting Enzyme (ACE) Inhibitors
• Angiotensin Receptor Blockers
• Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
• Mineralocorticoid Receptor Antagonists
• Others

United States Diabetic Nephropathy Market, By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Others